Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Stakes for Big Pharma in the Push Towards Full Enrollment in Part D

This article was originally published in RPM Report

Executive Summary

There are 4 million Medicare beneficiaries who have not yet joined the new drug benefit. The more who sign up in 2007, the better for Big Pharma.
Advertisement

Related Content

Medicare Rx in 2009: Re-Politicizing Drug Prices
Making Part D Stick: Lessons From the First Year of Medicare Rx
Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning
"Sweet Spot" Inside Drug Benefit Turns Sour
Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
Pfizer's Lipitor Sees Big Boost From Medicare
Preparing for Year Two of Part D: CMS Puts a Premium on Stability
Big Pharma's Secret Weapon
Preparing for Year Two of Part D: CMS Puts a Premium on Stability

Topics

Advertisement
UsernamePublicRestriction

Register

PS079994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel